IDM
Institut d' investigació
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublicaciones en colaboración con investigadores/as de AstraZeneca (United Kingdom) (6)
2023
-
Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies
British Journal of Clinical Pharmacology, Vol. 89, Núm. 9, pp. 2691-2702
2022
-
Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series
Pharmaceutics, Vol. 14, Núm. 5
2021
-
Current profile controlled transdermal delivery of pramipexole from an iontophoretic patch system in vitro and in vivo
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 166, pp. 175-181
2018
-
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
Journal of Extracellular Vesicles, Vol. 7, Núm. 1
-
Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 127, pp. 204-212
1994
-
Inhibitory activity of a series of coumarins on leukocyte eicosanoid generation
Agents and Actions, Vol. 42, Núm. 1-2, pp. 44-49